Last updated: July 29, 2025
Introduction
Spain Patent ES2981585, granted on December 9, 2020, represents a significant intellectual property asset within the pharmaceutical sector. This analysis delineates the patent's scope, claims, and the broader patent landscape, offering insight into its strategic relevance, competitive positioning, and potential implications for stakeholders in drug development and commercialization.
Patent Overview: ES2981585
Title: Method for diagnosing and/or predicting the response of patients to anti-cancer therapy
Filing Date: February 24, 2017
Grant Date: December 9, 2020
Applicants: Establecimiento Tecnológico, S.L. (ETEC), a Spanish biotechnology company specializing in predictive biomarkers
The patent pertains to diagnostic methods aimed at predicting patient responses to anticancer therapies, leveraging molecular biomarkers to guide personalized treatment regimes.
Scope of the Patent
Technical Field and Purpose
ES2981585 situates itself within precision medicine, specifically in diagnostic biomarkers for oncology therapies. Its primary technical objective is to enable clinicians to foresee the efficacy or resistance of patients to selected anticancer drugs, thereby optimizing individualized treatment plans.
Key Innovations
The patent introduces a biomarker-based diagnostic approach involving specific genetic or proteomic signatures. It emphasizes the identification and quantification of molecular markers—genes, transcripts, or proteins—that correlate with therapeutic response, particularly in cancer subtypes such as non-small cell lung carcinoma (NSCLC) and melanoma.
Claims Summary
The patent encompasses multiple claims, categorized broadly into independent and dependent claims, which establish the scope of protection.
Claims Analysis
1. Independent Claims
The core independent claims delineate the fundamental invention, typically covering the biomarker detection method and associated diagnostic platforms:
-
Claim 1: Describes a method for predicting the response of a patient to an anti-cancer therapy, involving detecting specific molecular markers in a biological sample. It emphasizes the use of quantitative measurements of these markers to determine likely therapeutic outcomes.
-
Claim 2: Extends Claim 1 by specifying the types of biomarkers (e.g., gene expression levels, protein presence) involved.
-
Claim 3: Details the method of obtaining the biological sample—blood, biopsy, or other bodily fluids—further clarifying its clinical applicability.
2. Dependent Claims
Dependent on the core claims, these specify particular markers, detection techniques, software algorithms, or interpretations:
-
Biomarkers: Examples include KRAS, EGFR, ALK mutations, or expression levels of PD-L1, which are well-established in predicting responses to targeted therapies like EGFR inhibitors, immunotherapies, or chemotherapy.
-
Detection Methods: Quantitative PCR, immunohistochemistry, next-generation sequencing (NGS), or proteomic arrays.
-
Interpretation Algorithms: The patent references computational tools that integrate biomarker data to generate a predictive score or classification output—further establishing its role as a diagnostic device.
Patent Landscape and Competitor Context
1. Similar Patents and Prior Art
The landscape for predictive biomarkers in oncology is highly dynamic. Several key patents and applications exist:
- US Patent US20190386094A1 (Cleveland Clinic), covers biomarker panels for predicting response to immunotherapy.
- EP Patent EP2765900B1 (Roche), addresses methods for detecting EGFR mutations.
- WO Patent WO2015195397A1 (Qiagen), on gene expression profiling for cancer prognosis.
ES2981585 contributes to this landscape by focusing on a combination of markers and specific predictive algorithms capable of guiding therapy decisions in a Spanish patent framework. Its emphasis on integrating multiple biomarkers and leveraging computational interpretation positions it uniquely.
2. Patent Family and Regional Coverage
The patent family appears primarily localized to Spain, with potential applications or counterparts in European Patent Convention (EPC) states and the United States. The strategic coverage aims to secure exclusive rights within Spain's healthcare sector, which can be a stepping stone toward broader European or international protection, either through national filings or PCT applications.
3. Patent Strengths and Limitations
Strengths:
- Specificity in biomarker combination enhances novelty and inventiveness over prior art focused on individual markers.
- Integration of detection methodology and computational algorithms addresses real-world clinical implementation.
Limitations:
- The rapid evolution of molecular diagnostics may threaten the patent’s long-term independence if incremental improvements are filed.
- As certain biomarkers (e.g., EGFR mutations) are extensively studied, patent novelty may hinge on the specific biomarker combinations and algorithms.
Implications for the Market
The patent’s scope centers on precision oncology, a rapidly expanding niche driven by molecular diagnostics. Its strategic importance includes:
- Commercially: Providing a proprietary diagnostic assay that can be integrated into personalized medicine protocols.
- Regulatory: Requiring validation/approval from Spanish and European health authorities before commercialization.
- Litigation and Licensing: Potential for licensing to diagnostic labs or collaborations with pharma companies offering companion diagnostics.
Conclusion
Patent ES2981585 solidifies a targeted approach to predicting patient responses to cancer therapies via molecular biomarkers and computational interpretation. Its claims, centered on specific biomarker combinations and methods, carve out a niche within Spain’s patent landscape. Its strength hinges on the robustness of its biomarker panel, the specificity of its detection techniques, and its integration into clinical workflows.
Key Takeaways
- Niche Focus: ES2981585 delivers a targeted diagnostic method within the growing field of personalized oncology, emphasizing biomarker-driven therapy prediction.
- Strategic Positioning: The patent’s regional scope secures competitive advantage in Spain, with potential expansion into broader European markets.
- Innovation Edge: Its combination of molecular detection and computational analysis creates a comprehensive diagnostic framework, differentiating it from standard biomarker patents.
- Market Potential: The rise of companion diagnostics heightens the commercial value of such patents, especially if they demonstrate clinical utility and regulatory approval.
- Legal Navigability: Future challenges could include demonstrating patentability over rapidly advancing prior art and ensuring broad enough claims for future growth.
FAQs
Q1: How does ES2981585 differ from existing biomarker patents?
A: It combines specific biomarker panels with integrated computational algorithms designed for predictive accuracy in therapy response, rather than focusing solely on individual markers.
Q2: What types of cancers does the patent primarily target?
A: The patent concentrates on cancers such as non-small cell lung carcinoma and melanoma, where molecular markers significantly inform treatment decisions.
Q3: Can this patent be licensed or used in other European countries?
A: Likely, through filing national or European patents claiming priority, subject to strategic IP rights management and validation processes.
Q4: What are the main challenges for commercializing this diagnostic method?
A: Validation through clinical trials, obtaining regulatory approval, and integrating the assay into existing diagnostic workflows.
Q5: How might future developments impact this patent?
A: Advances in biomarker discovery, sequencing technologies, or new predictive algorithms could erode its novelty unless further innovations are patented.
Sources:
[1] Spanish Patent Office (OEPM), Patent ES2981585.
[2] WIPO Patentscope, related harmonized patent applications.
[3] European Patent Office (EPO), similar biomarker diagnostic patents.
